Empowered Funds LLC Buys 18,487 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR)

Empowered Funds LLC grew its stake in OraSure Technologies, Inc. (NASDAQ:OSUR) by 5.1% in the fourth quarter, HoldingsChannel.com reports. The fund owned 377,906 shares of the medical instruments supplier’s stock after acquiring an additional 18,487 shares during the period. Empowered Funds LLC’s holdings in OraSure Technologies were worth $1,364,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Atom Investors LP bought a new stake in OraSure Technologies in the third quarter valued at approximately $49,000. Creative Planning acquired a new position in shares of OraSure Technologies in the 3rd quarter valued at $54,000. Intech Investment Management LLC acquired a new position in shares of OraSure Technologies in the 3rd quarter valued at $84,000. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of OraSure Technologies by 78.2% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 28,731 shares of the medical instruments supplier’s stock valued at $123,000 after buying an additional 12,604 shares in the last quarter. Finally, Ballentine Partners LLC acquired a new stake in OraSure Technologies during the 3rd quarter worth $159,000. 93.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, StockNews.com cut OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Thursday.

OraSure Technologies Stock Up 1.0 %

OraSure Technologies stock opened at $3.93 on Monday. The company has a 50 day moving average of $3.81 and a 200-day moving average of $4.04. OraSure Technologies, Inc. has a twelve month low of $3.52 and a twelve month high of $8.04. The stock has a market capitalization of $293.14 million, a PE ratio of 26.20 and a beta of 0.05.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.